Phase, Inc. is at the forefront of innovation in the field of microfluidics, leveraging its proprietary 3D printing technology to create advanced organ-on-a-chip models. This technology allows for the integration of essential components such as valves, sensors, and electrodes directly during the printing process, enabling the production of highly detailed and functional microfluidic devices. By utilizing biocompatible materials like PDMS, Phase is able to achieve a resolution that closely matches biological scales, which is crucial for accurately mimicking in vivo environments. This capability not only accelerates the development of new biomedical applications but also supports the growing demand for alternatives to traditional animal testing in drug development and toxicity assessments.

The company is actively collaborating with prestigious institutions such as Harvard Medical School, Georgia Tech, and Virginia Tech, backed by significant funding from the National Institutes of Health (NIH). These partnerships aim to enhance the functionality and applicability of microfluidic devices, particularly in addressing challenges related to neurological diseases and brain cancer. Phase's automated and reproducible manufacturing process facilitates rapid customization and scalability, positioning the company to lead advancements in biomanufacturing and pharmaceutical development. As regulatory bodies increasingly seek to reduce reliance on animal models, Phase's innovative solutions are set to play a pivotal role in the future of biomedical research and drug testing.

United States

Phase Technology designs, manufactures, sells and services test instruments to measure cold flow properties. The company's customers include oil refineries, ...

Phase

Company Details